April 2020
The user guidance of modern tablet presses is designed to be highly intuitive. In this connection, the TRI.EASY concept from Fette Compacting ensures an optimum combination of performance and simple operation. It therefore enables efficient tableting. This means that the user does not need to have detailed familiarity with the complex underlying pressing process. This is crucially affected by large numbers of parameters and machine settings. The Performance Consultants at Fette Compacting are usually brought in when the process is not running optimally. They have succeeded in raising the output in the production of a double layer tablet by 180 percent.
Continuous Manufacturing – Continuous need not be complex
The success of a Continuous Manufacturing line is primarily dependent on its PAT (Process Analytical Technology) system. With the right concept, users can ensure that all relevant parameters are recorded and sensors are integrated smoothly in the overall process.
March 2020
Corona Virus – interpack 2020 postponed
Corona Virus: interpack 2020 postponed – 25 February to 3 March 2021
February 2020
German Design Award Winner M Projekt Hamburg
Awarded – German Design Award for the trade fair appearance at Achema
July 2019
The i Series from Fette Compacting has stood for productive, flexible and unfailing tablet production for over decades. This will remain the case in the future, too, but with far more possibilities: the new i Series, which starts on 5 September 2019 with the single rotary press F10i, offers numerous innovative features.
1st Pharmaceutical Circle 2019
Our 1st Pharmaceutical Circle back in September exceeded all our expectations!
We are at the National Pharmaceutical Machinery Exposition 2019 (CIPM) Autumn China from November 05 - 07, 2019
April 2019
Double foresight – Lifetime Efficiency in practice
Lifetime Efficiency at Fette Compacting focuses on a new manner of collaboration with customers. It is based on an analysis of the entire machine park. Just how well this works is demonstrated by an international pharmaceutical company where data-supported scenarios have already revealed an optimization potential of several millions.
